Abstract
Calcium/calmodulin-dependent protein kinase IIδ (CaMKIIδ) is an important regulator of cardiac contractile function and dysfunction and may be an unwanted secondary target for anti-cancer drugs such as sunitinib and imatinib that have been reported to alter cardiac performance. This study aimed to determine whether anti-cancer kinase inhibitors may affect CaMKII activity and expression when administered in vivo.
Original language | English |
---|---|
Journal | British Journal of Pharmacology |
Early online date | 4 Jun 2015 |
DOIs | |
Publication status | Published - 2015 |
Keywords
- cardiac contractility
- calcium/calmodulin-dependent protein kinase II
- imatinib
- sunitinib
- cardiotoxicity
- phosphorylation